pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
NovaPharmaNews editorial coverage mentioning Amgen — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 2
- Drugs
- 86
- Patents
- 1
News & analysis
NovaPharmaNews articles mentioning Amgen — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Amgen — regulatory, clinical, and market analysis.
FDA Shakeup: Høeg's Departure and Amgen Drug Controversy
The FDA's dismissal of acting CDER director Tracy Høeg and the revelation of 20 patient deaths linked to Amgen's Tavneos in Japan create a dual crisis of regulatory leadership and drug safety. This analysis provides key takeaways, a timeline of events, and strategic implications for pharmaceutical BD and regulatory teams.
Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors
Recent leadership transitions at Amgen and Zai Lab signal potential shifts in strategic direction and operational focus. Understanding these changes is crucial for pharmaceutical business development, investment, and regulatory teams.
Amgen's Expanded Crackdown on 340B Program Misuse
Amgen has intensified its efforts to address what it claims is the misuse of the 340B program. This article explores the implications for the pharmaceutical sector.